Treatment of Turner Syndrome with Elevated FSH and Hypergonadotropic Hypogonadism in Girls Aged 11–12
Clinical Scenario
This protocol applies to girls aged 11–12 with confirmed Turner syndrome who have
hypergonadotropic hypogonadism, FSH elevated on
at least two sequential measurements, and no spontaneous thelarche. Persistently elevated FSH
in this context reflects severely impaired or absent ovarian function and identifies the
appropriate window for initiating estrogen replacement to support pubertal development.
Treatment Approach
The approach centres on starting low-dose estradiol (E2) replacement, with the transdermal
route preferred over oral administration. Dosing is initiated at the lowest recommended
starting level and is increased gradually over a multi-year period until adult replacement
dosage is reached. An alternative oral preparation exists for situations where neither the
primary nor second-line route is suitable.
Full titration schedule, route selection criteria, monitoring intervals, and dosing steps are in the complete structured protocol.
Treatment Goals
Therapy aims for progressive breast development and attainment of serum estradiol
concentrations of 100–150 pg/mL (350–500 pmol/L) at full adult replacement dosage.
Monitoring during dose escalation addresses breast development, height, uterine growth,
bone density, and serial serum estradiol levels.
References
- DOI: 10.1093/ejendo/lvae050
- We recommend initiation of low dose estrogen replacement between 11 and 12 years of age, if FSH is elevated on at least two sequential measurements.
- We recommend a starting dose of 7 mcg TD E2 or 0.25 mg oral E2, and increasing the dosing every 6-12 months.
- We suggest E2 transdermal (TD) route when possible, with oral E2 as second choice. Ethinyl estradiol has more risks but is better than no treatment.
- Estrogen dosage should be increased slowly to adult replacement dosage over 2-4 years.
- To optimize uterine growth during puberty and bone health in adulthood, we suggest multiple assessments of treatment effect, to include: breast development, height, uterine ultrasound, bone density, serum E2 concentrations, with the goal to achieve E2 concentrations of 100-150 pg mL⁻¹ (350-500 pmol L⁻¹) at full adult replacement.
View source ↗